Zevra Therapeutics (ZVRA) News Today → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Free ZVRA Stock Alerts $5.03 -0.13 (-2.52%) (As of 05:22 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineZevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - May 9 at 8:32 AMZevra Therapeutics to Participate at Upcoming Investor Eventsfinance.yahoo.com - May 9 at 8:32 AMFY2027 EPS Estimates for Zevra Therapeutics, Inc. Increased by Analyst (NASDAQ:ZVRA)marketbeat.com - May 9 at 8:23 AMZevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...finance.yahoo.com - May 9 at 3:31 AMZevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...finance.yahoo.com - May 8 at 5:28 PMZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024investorplace.com - May 8 at 1:14 PMZevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updatesglobenewswire.com - May 8 at 7:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - May 6 at 7:49 PMZevra Therapeutics (ZVRA) to Release Quarterly Earnings on Wednesdaymarketbeat.com - May 2 at 10:17 AMZevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024globenewswire.com - May 1 at 7:30 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Buy" from Analystsamericanbankingnews.com - May 1 at 3:12 AMZevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024finance.yahoo.com - April 29 at 11:11 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 28 at 9:45 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 20 at 12:00 PMZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meetingglobenewswire.com - April 15 at 5:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 12 at 9:30 AMZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facilityglobenewswire.com - April 10 at 7:30 AMZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facilityglobenewswire.com - April 10 at 7:30 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Analystsmarketbeat.com - April 6 at 2:43 AMHC Wainwright Brokers Lift Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 5 at 8:05 AMZevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 4 at 8:05 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAprnewswire.com - April 4 at 6:20 PMHC Wainwright Brokers Cut Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 4 at 9:44 AMZevra Therapeutics: Poised for Transformation and Growth Amidst Market Overreactionmarkets.businessinsider.com - April 3 at 6:34 PMBearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimatesfinance.yahoo.com - April 3 at 8:33 AMHC Wainwright Reiterates "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)marketbeat.com - April 3 at 8:24 AMRoth Capital Analysts Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - April 3 at 5:59 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAstockhouse.com - April 2 at 5:31 PMZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $18.00 at Maxim Groupmarketbeat.com - April 2 at 8:30 AMEquities Analysts Set Expectations for Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)marketbeat.com - April 2 at 6:54 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcriptinsidermonkey.com - April 1 at 1:02 PMZevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 9:09 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price Targetfinance.yahoo.com - March 31 at 1:02 PMZevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 11:47 AMWilliam Blair Research Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)marketbeat.com - March 29 at 8:37 AMZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMZevra Therapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 9:00 PMZevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatesglobenewswire.com - March 28 at 4:32 PMEarnings Outlook For Zevra Therapeuticsbenzinga.com - March 27 at 2:18 PMZevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomniaglobenewswire.com - March 26 at 4:30 PMZevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - March 25 at 4:30 PMKemPharm Inc (1GDA.DU)finance.yahoo.com - March 19 at 3:34 AMZevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024globenewswire.com - March 18 at 7:30 AMZevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years agofinance.yahoo.com - March 14 at 7:53 PMZevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at William Blairmarketbeat.com - March 12 at 8:21 AMZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Buy" from Brokeragesmarketbeat.com - March 12 at 8:19 AMQ4 2023 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Increased by Analystmarketbeat.com - March 7 at 6:40 AMRoth Capital Comments on Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)marketbeat.com - March 6 at 8:33 AMHC Wainwright Reaffirms "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)marketbeat.com - March 5 at 8:17 AMZevra Therapeutics Says FDA Extends NDA Review Period For Arimoclomolmarkets.businessinsider.com - March 4 at 8:47 AM Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. ZVRA Media Mentions By Week ZVRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼-0.180.36▲Average Medical News Sentiment ZVRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼102▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Design Therapeutics News Veru News G1 Therapeutics News Eliem Therapeutics News Telomir Pharmaceuticals News Trevi Therapeutics News Lifecore Biomedical News Alimera Sciences News Acrivon Therapeutics News Prelude Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
